Robot technology identifies a Parkinsonian therapeutics repurpose to target stem cells of glioblastoma.
CNS Oncol
; 9(2): CNS58, 2020 06.
Article
en En
| MEDLINE
| ID: mdl-32462934
ABSTRACT
Aim:
Glioblastoma is a heterogeneous lethal disease, regulated by a stem-cell hierarchy and the neurotransmitter microenvironment. The identification of chemotherapies targeting individual cancer stem cells is a clinical need.Methodology:
A robotic workstation was programmed to perform a drug concentration to cell-growth analysis on an in vitro model of glioblastoma stem cells (GSCs). Mode-of-action analysis of the selected top substance was performed with manual repetition assays and acquisition of further parameters.Results:
We identified 22 therapeutic potential substances. Three suggested a repurpose potential of neurotransmitter signal-modulating agents to target GSCs, out of which the Parkinson's therapeutic trihexyphenidyl was most effective. Manual repetition assays and initial mode of action characterization revealed suppression of cell proliferation, cell cycle and survival.Conclusion:
Anti-neurotransmitter signaling directed therapy has potential to target GSCs. We established a drug testing facility that is able to define a mid-scale chemo responsome of in vitro cancer models, possibly also suitable for other cell systems.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Células Madre Neoplásicas
/
Robótica
/
Neoplasias Encefálicas
/
Glioblastoma
/
Neurotransmisores
/
Reposicionamiento de Medicamentos
/
Antineoplásicos
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
CNS Oncol
Año:
2020
Tipo del documento:
Article
País de afiliación:
Alemania